Format

Send to

Choose Destination
Clin Rheumatol. 2016 May;35(5):1383-8. doi: 10.1007/s10067-014-2669-0. Epub 2014 May 15.

The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature.

Author information

1
Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy. rossana.scrivo@uniroma1.it.
2
Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy.
3
Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy.
4
Dipartimento Malattie Polmonari, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
5
Cattedra di Gastroenterologia, Università Campus Bio-Medico, Rome, Italy.
6
UOC Malattie Infettive, Fondazione Eleonora Lorillard Spencer Cenci, Sapienza Università di Roma (Polo Pontino), Latina, Italy.

Abstract

Conversions and reversions of interferon-gamma (IFN-γ) release assays (IGRAs) were observed when these tests were repeated over time in the same individuals, including those treated with biological agents. In most studies, the variability of IFN-γ plasma levels was not paralleled by clinical change, but a few exceptions exist, in which IGRA conversion predicted the emergence of active tuberculosis (TB). We report the case of a Peruvian patient with rheumatoid arthritis (RA) and Crohn's disease scheduled for treatment with adalimumab. TB screening demonstrated latent TB infection (LTBI), and the patient was started on isoniazid (INH) for 9 months. Adalimumab was initiated after 1 month since INH. QuantiFERON-TB Gold In-Tube, one of the IGRAs currently available, was serially repeated to monitor the status of TB infection during treatment with the biological agent. The patient developed active TB preceded by progressively rising levels of released IFN-γ. We came to know that she had withdrawn INH after 2 months on her own initiative. Considering the low rate of INH completion, serial IGRAs may help in the clinical vigilance during prophylaxis as well as anti-TNF treatment, at least in patients presenting other risk factors aside from the state of immunosuppression.

KEYWORDS:

Adalimumab; IGRA; QuantiFERON-TB Gold In-Tube; Rheumatoid arthritis; TNF antagonists; Tuberculosis

PMID:
24827875
DOI:
10.1007/s10067-014-2669-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center